Home Isolation and crystal structure of bufotalinin — methanol (1/1), C25H34O7
Article Open Access

Isolation and crystal structure of bufotalinin — methanol (1/1), C25H34O7

  • Guo-Qiang Li , Yi-Ting Zhao , Qing-Peng Xu , Hai-Yan Tian , Peng-ran Guo and Fu-wang Wu EMAIL logo
Published/Copyright: May 13, 2019

Abstract

C25H34O7, monoclinic, P21 (no. 4), a = 9.24730(10) Å, b = 9.9061(2) Å, c = 12.5907(2) Å, β = 101.264(2)°, V = 1131.15(3) Å3, Z = 2, Rgt(F) = 0.0380, wRref(F2) = 0.1025, T = 173 K.

CCDC no.: 1908020

The molecular structure and the solvate molecule methanol is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal:Colourless block
Size:0.28 × 0.26 × 0.20 mm
Wavelength:Cu Kα radiation (1.54178 Å)
μ:0.78 mm−1
Diffractometer, scan mode:Gemini S ultra, ω
θmax, completeness:62.8°, 99%
N(hkl)measured, N(hkl)unique, Rint:17729, 3544, 0.026
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3516
N(param)refined:297
Programs:CrysAlisPRO [1], SHELX [2]
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
O10.0734(3)1.0505(3)−0.06854(19)0.0414(6)
H1−0.023(7)1.091(7)−0.077(5)0.098(19)*
O20.2639(2)0.8830(2)0.04728(17)0.0330(5)
H20.18130.90980.01380.049*
O30.8950(2)1.1349(2)0.27709(15)0.0309(5)
O40.2733(3)0.9575(3)0.3296(2)0.0546(7)
O51.1480(3)1.3115(3)0.67529(18)0.0419(6)
O61.3620(3)1.2062(3)0.72423(19)0.0484(6)
C10.1910(3)1.1351(3)0.1577(2)0.0317(7)
H1A0.11251.06560.14750.038*
H1B0.18381.18730.22350.038*
C20.1638(3)1.2303(3)0.0600(3)0.0363(7)
H2A0.06351.26890.05130.044*
H2B0.23541.30570.07330.044*
C30.1792(4)1.1577(3)−0.0432(2)0.0351(7)
H30.16641.2234−0.10460.042*
C40.3304(3)1.0925(3)−0.0286(2)0.0296(7)
H4A0.40611.1644−0.01920.035*
H4B0.33721.0421−0.09530.035*
C50.3647(3)0.9964(3)0.0677(2)0.0256(6)
C60.5187(3)0.9367(3)0.0758(2)0.0302(7)
H6A0.52820.85630.12340.036*
H6B0.53040.90650.00300.036*
C70.6421(3)1.0358(4)0.1202(2)0.0312(7)
H7A0.63991.11230.06930.037*
H7B0.73870.99010.12720.037*
C80.6230(3)1.0883(3)0.2306(2)0.0249(6)
H80.62051.00820.27860.030*
C90.4736(3)1.1625(3)0.2205(2)0.0243(6)
H90.47181.23640.16610.029*
C100.3428(3)1.0640(3)0.1755(2)0.0249(6)
C110.4597(3)1.2286(3)0.3279(2)0.0305(7)
H11A0.36921.28460.31640.037*
H11B0.44881.15710.38070.037*
C120.5918(3)1.3170(3)0.3756(3)0.0337(7)
H12A0.57711.35440.44560.040*
H12B0.59701.39370.32610.040*
C130.7393(3)1.2390(3)0.3936(2)0.0272(6)
C140.7476(3)1.1778(3)0.2846(2)0.0264(6)
C150.8403(3)1.2640(4)0.2313(3)0.0347(7)
H150.81601.27580.15090.042*
C160.8972(4)1.3815(4)0.3022(3)0.0392(8)
H16A0.84421.46530.27510.047*
H16B1.00391.39480.30460.047*
C170.8683(3)1.3443(3)0.4158(2)0.0307(7)
H170.82931.42710.44590.037*
C180.7484(3)1.1350(3)0.4840(2)0.0329(7)
H18A0.74761.18130.55260.049*
H18B0.83981.08300.48990.049*
H18C0.66361.07390.46740.049*
C190.3435(3)0.9536(4)0.2589(2)0.0327(7)
H190.40310.87640.25490.039*
C201.0066(3)1.3021(3)0.4951(2)0.0285(6)
C211.0272(3)1.3449(4)0.5990(3)0.0356(7)
H210.95401.40080.61980.043*
C221.1207(3)1.2213(3)0.4674(2)0.0315(7)
H221.11171.18940.39520.038*
C231.2416(3)1.1892(3)0.5418(2)0.0287(6)
H231.31671.13640.52040.034*
C241.2598(3)1.2321(3)0.6514(3)0.0332(7)
O71.7878(4)1.1263(4)0.8885(3)0.0737(10)
H71.78531.21110.88940.111*
C251.7137(6)1.0812(5)0.7918(4)0.0723(14)
H25A1.73571.13930.73400.108*
H25B1.60761.08320.79100.108*
H25C1.74420.98850.78030.108*

Source of material

The ChanSu crude drug was purchased from Guangzhou qingping medicine market, Guangdong, China. Powder of ChanSu (100 g) was dissolved in water and extracted three times with acetate at room temperature. The extracts were concentrated in vacuum to give a residue (25 g). The obtained solid was purified by silica gel column chromatography with petroleum ether-acetone as mobile phase and preparative liquid chromatography. Then the title compound (systematic name: (1R,3aS,5aS,7S,9aS,11aR)-5a,7-dihydroxy-11a-methyl-1-(2-oxo-2H-pyran-5-yl)tetradecahydronaphtho[1′,2′:6,7]indeno[1,7a-b]oxirene-9a(1H)-carbaldehyde was obtained and crystallized in methanol. The title compound is a 1/1 cocrystal of the organic target molecule and methanol (cf. the figure).

Experimental details

The C-bound H atoms were positioned geometrically and were included in the refinement in the riding-model approximation. The crystal structure was solved by direct method and refined by full-matrix least-squares refinement with SHELX program [2]. The Flack-Parsons parameter was −0.01(6) based on 1593 quotients [(I+)−(I−)]/[(I+)+(I−)] [2].

Comment

ChanSu is a valuable medicinal material produced from the skin secretions of Bufo gargarizans Cantor or Bufo melanostictus Schneider. Earlier studies have demonstrated bufadienolides were the main active ingredients in ChanSu [3], [4], [5], [6]. These compounds have a δ-lactone at C17 position and possess multiple biological activities such as antivirus and anticancer [7], [8], [9], [10], [11].

The crystals of title compound, bufotalinin methanol monosolvate, were obtained by slow evaporation from a methanol solution. The title compound is composed of five rings, one five-numbered and four six-numbered. The torsion angles of O1—C1—C2—C3 and O2—C5—C10—C19 are 61.4(3), 165.1(2)° respectively. The dihedral angle between the planes of the lactone ring (mean deviation 0.0071 Å) and the epoxy group is 74.6(1)°. A short intramolecular interaction between the C5 hydroxy and C3 hydroxy is present [O2—H2⋯O1 = 1.90 Å, 147°]. The bond lengths and in general all geometric parameters are in the expected ranges [12], [13].

Award Identifier / Grant number: 31701670

Award Identifier / Grant number: 2016A030310079

Funding statement: This work was supported financially by the National Natural Science Foundation of China (31701670) and the Natural Science Foundation of Guangdong Province (Grant 2016A030310079), Postgraduate demonstration course construction foundation of Guangdong Education Department (2016SFKC-43), the Fundamental Research Funds for the Central Universities (Grant gg040971), the Student academic fund of Foshan University.

References

1. Agilent Technologies. CrysAlisPRO Software system. Agilent Technologies UK Ltd, Oxford, UK (2015).Search in Google Scholar

2. Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Search in Google Scholar

3. Xin, X. L.; Lan, R.; Huang, J.; Wang, X. J.; Jia, J. M.: A new cytotoxic bufadienolide from Chinese medicine Chansu. Chin. Chem. Lett. 19 (2008) 1445–1446.10.1016/j.cclet.2008.09.037Search in Google Scholar

4. Sun, Y. S.; Bi, J. J.; Zhuang, L.; Ye, B. X.: Ultrasound-assisted extraction of three bufadienolides from Chinese medicine ChanSu. Ultrason. Sonochem. 19 (2012) 1150–1154.10.1016/j.ultsonch.2012.03.003Search in Google Scholar

5. Ye, M.; Guo, H.; Guo, H. Z.; Han, J.; Guo, D. A.: Simultaneous determination of cytotoxic bufadienolides in the Chinese medicine ChanSu by high-performance liquid chromatography coupled with photodiode array and mass spectrometry detections. J. Chromatogr. B 838 (2006) 86–95.10.1016/j.jchromb.2006.04.042Search in Google Scholar

6. Tian, H. Y.; Wang, L.; Zhang, X. Q.; Wang, Y.; Zhang, D. M.; Jiang, R. W.; Liu, Z.; Liu, J. S.; Li, Y. L.; Ye, W. C.: Bufogargarizins A and B: two novel 19-norbufadienolides with unprecedented skeletons from the venom of Bufo bufo gargarizans. Chem. Eur. J. 16 (2010) 10989–10993.10.1002/chem.201000847Search in Google Scholar

7. Zhao, Y. Z.; Zhang, Y. Y.; Han, H.; Fan, R. P.; Hu, Y.; Zhong, L.; Kou, J. P.; Yu, B. Y.: Advances in the antitumor activities and mechanisms of action of steroidal saponins. Chin. J. Nat. Med. 16 (2018) 732–748.10.1016/S1875-5364(18)30113-4Search in Google Scholar

8. Tian, H. Y.; Yuan, X. F.; Jin, L.; Li, J.; Luo, C.; Ye, W. C.; Jiang, R. W.: A bufadienolide derived androgen receptor antagonist with inhibitory activities against prostate cancer cells. Chem. Biol. Interact. 207 (2014) 16–22.10.1016/j.cbi.2013.10.020Search in Google Scholar PubMed

9. Tian, H. Y.; Wang, L.; Zhang, X. Q.; Zhang, D. M.; Wang, Y.; Liu, Z.; Liu, J. S.; Jiang, R. W.; Ye, W. C.: New bufadienolides and C23 steroids from the venom of Bufo bufo gargarizans. Steroids 75 (2010) 884–890.10.1016/j.steroids.2010.05.013Search in Google Scholar PubMed

10. Tian, H. Y.; Luo, S. L.; Liu, J. S.; Wang, L.; Wang, Y.; Zhang, D. M.; Liu, Z.; Zhang, X. Q.; Jiang, R. W.; Ye, W. C.: C23 Steroids from the venom of Bufo bufo gargarizans. J. Nat. Prod. 76 (2013) 1842–1847.10.1021/np400174fSearch in Google Scholar PubMed

11. Zhang, P.-W.; Tian, H.-Y.; Nie, Q.-L.; Wang, L.; Zhou, S.-W.; Ye, W.-C.; Zhang, D.-M.; Jiang, R.-W.: Structures and inhibitory activity against breast cancer cells of new bufadienolides from the eggs of toad Bufo bufo gargarizans. RSC Adv. 6 (2016) 93832–93841.10.1039/C6RA18676ASearch in Google Scholar

12. Kalman, A.; Fulop, V.; Argay, G.; Ribar, B.; Lazar, D.; Zivanov-Stakic, D.; Vladimirov, S.: Structures of two bufadienolides:bufotalin (3β,14-dihydroxy-16β-acetoxy-5β,14β-bufa-20,22-dienolide) and cinobufotalin (3β,5β-dihydroxy-14,15β-epoxy-16β-acetoxy-5β,14β-bufa-20,22-dienolide). Acta Crystallogr. C 44 (1988) 1634–1638.10.1107/S0108270188005724Search in Google Scholar

13. Argay, G.; Kalman, A.; Ribar, B.; Vladimirov, S.; Zivanov-Stakic, D.: Structures of two related bufadienolides: gamabufotalin (3β,11α,14-trihydroxy-5β,14β]-bufa-20,22-dienolide) and arenobufagin (3β,11α,14-trihydroxy-12-oxo-5β,14β-bufa-20,22-dienolide). Acta Crystallog. C 45 (1987) 922–926.10.1107/S0108270187093569Search in Google Scholar

Received: 2019-02-24
Accepted: 2019-04-04
Published Online: 2019-05-13
Published in Print: 2019-09-25

©2019 Guo-Qiang Li et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 Public License.

Articles in the same Issue

  1. Frontmatter
  2. Crystal structure of poly[diaqua-(μ8-1,1′:2′,1′′-terphenyl-3,3′′,4′,5′-tetracarboxylato-κ8O1:O2:O3:O4:O5:O6:O7:O8)dicopper(II)], C22H14Cu2O10
  3. Crystal structure of 2-((1H-benzo[d]imidazol-2-ylimino)methyl)-4,6-di-tert-butylphenol, C22H27N3O
  4. Crystal structure of (4-ethoxynaphthalen-1-yl)(furan-2-yl)methanone, C17H14O3
  5. Crystal structure of 1-nonylpyridazin-1-ium iodide, C13H23N2I
  6. Crystal structure of bis[diaqua(1,10-phenanthroline-κ2N, N′)-copper(II)]diphenylphosphopentamolybdate dihydrate, C36H38Cu2Mo5N4O27P2
  7. The crystal structure of tetrakis(imidazole)-copper(I) hexafluorophosphate, C12H16CuF6PN8
  8. The crystal structure of dimethyl ((3,5-di-tert-butyl-4-hydroxyphenyl)(phenyl)methyl)phosphonate, C23H33O4P
  9. Crystal structure of diaqua-bis(1,10-phenanthroline κ2N,N′)nickel(II) trifluoroacetate- trifluoroacetic acid (1/1), C30H21F9N4NiO8
  10. Crystal structure of 2-(naphthalen-2-yl)-1,8-naphthyridine, C18H12N2
  11. Synthesis and crystal structure of a new polymorph of diisopropylammonium trichloroacetate, C8H16Cl3NO2
  12. Crystal structure of dimethanol-bis(1-((2-methyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κN)-bis(thiocyanato-κN)cadmium(II) C34H34CdN12O2S2
  13. Crystal structure of ethyl 2,2-difluoro-2-(7-methoxy-2-oxo-2H-chromen-3-yl)acetate, C14H12F2O5
  14. The crystal structure of bis[μ2-(N,N-diethylcarbamodithioato-κSSS′)] bis[1′-(diphenylphosphino-κP)-1-cyanoferrocene]disilver(I), C56H56Ag2Fe2N4P2S4
  15. Crystal structure of bis(di-n-butylammonium) tetrachloridodiphenylstannate(IV), C28H50Cl4N2Sn
  16. The crystal structure of poly[(μ5-2-((5-bromo-3-formyl-2-hydroxybenzylidene)amino)benzenesulfonato-κ6O:O:O,O′:O′:O′′)sodium(I)], C13H9O4NSBrNa
  17. Crystal structure of catena-{poly[bis(O,O′-diethyldithiophosphato-S)-(μ2-1,2-bis(4-pyridylmethylene)hydrazine-N,N′)-zinc(II)] di-acetonitrile solvate}, {C20H30N4O4P2S4Zn ⋅ 2 C2H3N}n
  18. Halogen and hydrogen bonding in the layered crystal structure of 2-iodoanilinium triiodide, C6H7I4N
  19. Crystal structure of cyclohexane-1,4-diammonium 2-[(2-carboxylatophenyl)disulfanyl]benzoate — dimethylformamide — monohydrate (1/1/1), [C6H16N2][C14H8O4S2] ⋅ C3H7NO⋅H2O
  20. The synthesis and crystal structure of isobutyl 5-amino-1-(2,6-dichloro-4-(trifluoromethyl)phenyl)-4-((trifluoromethyl)sulfinyl)-1H-pyrazole-3-carboxylate, C16H13Cl2F6N3O3S
  21. Isolation and crystal structure of bufotalinin — methanol (1/1), C25H34O7
  22. Crystal structure of benzylbis(1,3-diphenylpropane-1,3-dionato-κ2O,O′) chloridotin(IV), C37H29ClO4Sn
  23. Crystal structure of Bis{1-[(benzotriazol-1-yl)methyl]-1-H-1,3-(2-methyl-imidazol)}diiodidocadmium(II), [Cd(C11H11N5)2I2], C22H22N10I2Cd
  24. Crystal structure of 4-isobutoxybenzaldehyde oxime, C11H15NO2
  25. The crystal structure of bis(acetato-κ1O)-bis(N′-hydroxypyrimidine-2-carboximidamide-κ2N,N′)manganese(II) — methanol (1/2), C14H18MnN8O6, 2(CH3OH)′
  26. Crystal structure of poly[bis(μ2-bis(4-(1H-imidazol-1-yl)phenyl)amine-κ2N:N′)-bis(nitrato-κO)cadmium(II)], C36H30CdN12O6
  27. Crystal structure and optical properties of 1,6-bis(methylthio)pyrene, C18H14S2
  28. The crystal structure of hexaquamagnesium(II) bis(3,4-dinitropyrazol-1-ide), C6H14MgN8O14
  29. Halogen bonds in the crystal structure of 4,3:5,4-terpyridine – 1,4-diiodotetrafluorobenzene (1/1), C21H11F4I2N3
  30. Crystal structure and photochromic properties of a novel photochromic perfluordiarylethene containing a triazole bridged pyridine group moiety, C24H18F6N4S2
  31. Crystal structure of bis[(μ3-oxido)-(μ2-(N,N-diisopropylthiocarbamoylthio) acetato-κ2O,O′)-((N,N-diisopropylthiocarbamoylthio)acetato-κO)-bis(di-4-methylbenzyl-tin(IV))], C100H136N4O10S8Sn4
  32. Crystal structure of dibromidobis(4-bromobenzyl)tin(IV), C14H12Br4Sn
  33. The crystal structure of (4Z)-2-[(E)-(1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene)methyl]-4-[(1-ethyl-3,3-dimethyl-3H-indolium-2-yl)methylidene]-3-oxocyclobut-1-en-1-olate, C30H32N2O2
  34. The crystal structure of (E)-3-(4-(dimethylamino)styryl)-5,5-dimethylcyclohex-2-en-1-one, C18H23NO
  35. Crystal structure of dihydrazinium 1H-pyrazole-3,5-dicarboxylate, C5H12N6O4
  36. Crystal structure of poly[μ2-1,4-bis((1H-imidazol-1-yl)methyl)benzene-κ2N:N′)-(μ2-4-sulfidobenzoate-κ2O:S)cobalt(II)] dihydrate, C42H44Co2N8O7S2
  37. Crystal structure of 8-(3,4-dimethylbenzylidene)-6,10-dioxaspiro[4.5]decane-7,9-dione, C17H18O4
  38. Crystal structure of 4-(2-bromo-4-(6-morpholino-3-phenyl-3H-benzo[f]chromen-3-yl) cyclohexa-2,5-dien-1-yl)morpholine, C33H31BrN2O
  39. Synthesis and crystal structure of 2-((1-phenyl-3-(thiophen-2-yl)-1H-pyrazol-4-yl)methylene)-2,3-dihydro-1H-inden-1-one, C23H16N2OS
  40. Crystal structure of poly[(μ2-1,1′-(oxybis(4,1-phenylene)bis(1H-imidazole)-κ2N,N′)(μ2-1,3-benzenecarboxylato-κ3O,O′:O′′)zinc(II)] dihydrate, C26H22N4O7Zn
  41. Crystal structure of diaqua-bis(cinnamato-κ2O,O′)zinc(II), C18H18ZnO6
  42. Crystal structure of 2-(prop-2-yn-1-yloxy)-1-naphthaldehyde, C14H10O2
  43. Crystal structure and photochromic properties of 1-(2-methyl-5-phenyl-3-thienyl)-2-{2-methyl-5-[4-(9-fluorenone hydrazone)-phenyl]-3-thienyl}perfluorocyclopentene, C41H26F6N2S2
  44. Hydrothermal synthesis and crystal structure of cylo[tetraaqua-bis(μ2-1,4-bis(1H-benzo[d]imidazol-1-yl)but-2-ene-κ2N:N′)-bis(μ2-4-nitro-phthalate-κ2O,O′)dinickel(II)], C26H23N5O8Ni
  45. Crystal structure of 3-[methyl(phenyl)amino]-1-phenylthiourea, C14H15N3S
  46. Crystal structure of 1-(4-chlorophenyl)-3-[methyl(phenyl)amino]thiourea, C14H14ClN3S
  47. Crystal structure of 2-tert-butyl-1H-imidazo[4,5-b]pyridine, C10H13N3
  48. Crystal structure of 5-carboxy-2-(2-carboxyphenyl)-1H-imidazol-3-ium-4-carboxylate dihydrate, C12H8N2O6⋅2(H2O)
  49. The crystal structure of dichlorido-μ2-dichlorido-(η2-1,4-bis(4-vinylbenzyl)-1,4-diazabicyclo[2.2.2]octane-1,4-diium)dicopper(I), C24H30N2Cu2Cl4
  50. Crystal structure of 4-bromobenzyl (Z)-N-(adamantan-1-yl)morpholine-4-carbothioimidate, C22H29BrN2OS
  51. Crystal structure of (4S,4aS,6aR,6bR,12aS,12bR,14aS,14bR)-3,3,6a,6b,9,9,12a-heptamethyloctadecahydro-1H,3H-4,14b-ethanophenanthro[1,2-h]isochromene-1(6bH)-one, C30H48O2
  52. Crystal structure of 3,5-bis(trifluoromethyl)benzyl (Z)-N′-(adamantan-1-yl)-4-phenylpiperazine-1-carbothioimidate, C30H33F6N3S
  53. The crystal structure of 3-methoxyphenanthridin-6(5H)-one, C14H11NO2
  54. Crystal structure of 4-(5,5-difluoro-1,3,7,9-tetramethyl-3H,5H-5λ4-dipyrrolo[1,2-c:2′,1′-f][1,3,2]diazaborinin-10-yl)pyridin-1-ium tetraiodidoferrate(III), C18H19BF2FeI4N3
  55. Crystal structure of 2-(3-methoxyphenyl)-3-((phenylsulfonyl)methyl)imidazo[1,2-a]pyridine, C21H18N2O3S
  56. Crystal structure of [(2-(2-chlorophenyl)-5-ethyl-1,3-dioxane-5-carboxylato-κ2O,O′) (5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)]nickel(II) perchlorate, C29H50Cl2N4NiO8
  57. Crystal structure of (Z)-6-(dimethylamino)-3,3-bis(4-(dimethylamino)phenyl)-2-(2-(quinoxalin-2-ylmethylene)hydrazinyl)-2,3-dihydroinden-1-one, C35H35N7O
  58. 5-Methyl-N′-[5-methyl-1-(4-methylphenyl)-1H-1,2,3-triazole-4-carbonyl]-1-(4-methylphenyl)-1H-1,2,3-triazole-4-carbohydrazide, C22H22N8O2
  59. Crystal structure of 2,3-dichloro-6-methoxyquinoxaline, C9H6Cl2N2O
  60. Synthesis and crystal structure of 7-chloro-2-(ethylsulfinyl)-6-fluoro-3-(1H-pyrazole-1-yl)-4H-thiochromen-4-one, C13H10FN3OS2
  61. Crystal structure of 4-ethylpiperazine-1-carbothioic dithioperoxyanhydride, C14H26N4S4
  62. Crystal structure of 2-(2-(6-methylpyridin-2-yl)naphthalen-1-yl)pyrimidine, C20H15N3
  63. The crystal structure of N′-((1E,2E)-4-(7-methoxy-2-oxo-2H-chromen-8-yl)-2-methylbut-2-en-1-ylidene)-3-methylbenzohydrazide, C23H22N2O4
  64. Crystal structure of catena-poly[(μ2-isophthalato-κ2O:O′)-(2,5-di(pyrazin-2-yl)-4,4′-bipyridine-κ3N,N′,N′′)zinc(II)] — water (2/5), C26H21N6O6.5Zn
  65. Crystal structure of (3E,5E)-3,5-bis(3-nitrobenzylidene)-1-((4-(trifluoromethyl)phenyl)sulfonyl)piperidin-4-one — dichloromethane (2/1), C53H38Cl2F6N6O14S2
  66. Crystal structure of (μ2-oxido)-bis(N,N′-o-phenylenebis(salicylideneiminato))diiron(III) — N,N′-dimethylformamide, C47H43Fe2N4O9
  67. Crystal structure of N1,N3-bis(2-hydroxyethyl)-N1, N1,N3,N3-tetramethylpropane-1,3-diaminium dibromide, C11H28Br2N2O2
  68. Crystal structure of (E)-N-(4-chlorophenyl)-1-(pyridin-2-yl)methanimine, C12H9ClN2
  69. Crystal structure of 8-bromo-6-oxo-2-phenyl-6H-pyrrolo[3,2,1-ij]quinoline-5-carbaldehyde, C18H11BrNO2
  70. Crystal structure of 1,4-bis(2-azidoethyl)piperazine-1,4-diium dichloride trihydrate, C8H18N8Cl2 ⋅ 3 H2O
  71. Crystal structure of (E)-4-bromo-N-(pyridin-2-ylmethylene)aniline, C12H9BrN2
  72. Crystal structure of bis[(2-(3-bromophenyl)-5-methyl-1,3-dioxane-5-carboxylato-κ-O)-(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)]nickel(II), C40H60Br2N4NiO8
  73. The crystal structure of (1E,2E)-2-methyl-4-((7-oxo-7H-furo[3,2-g]chromen-9-yl)oxy)but-2-enal O-isonicotinoyl oxime–trichloromethane (3/1), C67H49Cl3N6O18
  74. Crystal structure of 3-(2-ethoxy-2-oxoethyl)-1-methyl-1H-imidazol-3-ium hexafluoridophosphate(V), C8H13F6N2O2P
  75. Crystal structure of bis[(2-(2-bromophenyl)-5-ethyl-1,3-dioxane-5-carboxylato-κO)-(5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N′′′)]nickel(II) hemihydrate C42H65Br2N4NiO8.5
  76. The crystal structure of N-(7-(4-fluorobenzylidene)-3-(4-fluorophenyl)-3,3a,4,5,6,7-hexahydro-2H-indazole-2-carbonothioyl)benzamide, C28H23F2N3OS
  77. The crystal structure of N1,N4-bis(pyridin-3-yl)cyclohexane-1,4-dicarboxamide, C18H20N4O2
  78. Crystal structure of (E)-2-(3,6-bis(ethylamino)-2,7-dimethyl-9H-xanthen-9-yl)-N′-((6-methylpyridin-2-yl)methylene)benzohydrazide – methanol (1/1), C34H37N5O3
  79. Crystal structure of 2-oxo-1-(pyrimidin-5-ylmethyl)-3-(3-(trifluoromethyl)phenyl)-1,2-dihydro-5l4-pyrido[1,2-a]pyrimidin-4-olate, C20H13F3N4O2
  80. Crystal structure of poly[(μ3-9H-carbazole-3,6-dicarboxylato-κ3O1: O2: O3)(μ2-4-(pyridin-4-yl)pyridine-κ2N1:N1′)zinc(II)], C19H11N2O4Zn
  81. Crystal structure of (E)-N′-((1,8-dihydropyren-1-yl)-methylene)picolinohydrazide, C23H15N3O
  82. Crystal structure of catena-poly{[μ2-1,2-bis(diphenylphosphino)ethane]dichloridocadmium(II)}, C26H24CdCl2P2
  83. Crystal structure of the 1:2 co-crystal between N,N′-bis(4-pyridylmethyl)oxalamide and acetic acid as a dihydrate, C14H14N4O2⋅2 C2H4O2⋅2 H2O
  84. Crystal structure of the co-crystal N,N′-bis(3-pyridylmethyl)oxalamide acetic acid (1/2), C14H14N4O2⋅2C2H4O2
  85. Crystal structure of the co-crystal N,N′-bis(4-pyridylmethyl)oxalamide and 2,3,5,6-tetrafluoro-1,4-di-iodobenzene (1/1), C14H14N4O2⋅C6F4I2
  86. Crystal structure of the co-crystal 4-[(4-carboxyphenyl)disulfanyl]benzoic acid–(1E,4E)-1-N,4-N-bis(pyridin-4-ylmethylidene)cyclohexane-1,4-diamine (1/1), C14H10O4S2⋅C18H20N4
  87. Crystal structure of hexacarbonyl-bis(μ2-di-n-propyldithiocarbamato-κ3S,S′:S3S:S:S′)-di-rhenium(I), C20H28N2O6Re2S4
  88. Crystal structure of fac-tricarbonyl-morpholine-κN-(morpholinocarbamodithioato-κ2S,S′)rhenium(I), C12H17N2O5ReS2
Downloaded on 9.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2019-0138/html
Scroll to top button